Cleerly Health improves the diagnosis and treatment of heart disease using artificial intelligence to analyze coronary computed tomography angiography (CCTA) imaging. This technology helps clinicians identify atherosclerosis earlier and create personalized treatment plans based on detailed insights into plaque types. Cleerly stands out by offering a comprehensive digital cardiovascular care management program that provides actionable clinical insights. The goal is to enhance patient outcomes and financial results for healthcare providers.

Vensana Capital

Mirae Asset Capital

Cigna Ventures

Breyer Capital

Insight Partners

DigiTx Partners

General Catalyst

Battery Ventures

New Leaf Venture Partners

General Catalyst Partners

LRVHealth

T. Rowe Price

Peter Thiel

Fidelity Investments

New Leaf Ventures

Novartis

Piper Sandler

Esplanade Ventures

Cavendish Impact Capital

ImpactAssets

American College of Cardiology

AI & Machine Learning

Healthcare

Cleerly

DENVER--(BUSINESS WIRE)--Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Coronary Artery Disease (CAD) Staging System. The CAD Staging System is a noninvasive imaging-based investigational software device that analyzes important and actionable features of coronary atherosclerosis, stenosis and ischemia. Its purpose is to support physicians with a more accurate and personalized risk assessment for patients at risk of major adverse cardiovascular events (MACE), including heart attacks, before they happen. The FDA’s Breakthrough Device Designation is granted for technologies that have the possibility to encourage more effective diagnosis or treatment for life-threatening or irreversibly debilitating diseases. The FDA supports these novel technologies to ensure timely availability when no approved alternatives exist and/or because these technologies hold potential for considerable improvement over existing approved alternatives for patients

Cleerly® Receives Fda Breakthrough Device Designation For Heart Disease Risk Staging System

DENVER--(BUSINESS WIRE)--Cleerly, the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Food and Drug Administration (FDA)-cleared Cleerly ISCHEMIA software device applied to a non-invasive coronary CT angiogram (CCTA) can be billed using the new Category I CPT® code 75580. The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making. The Category I CPT® code is an addition to the Category III CPT® codes (CPT® 0623T, 0624T, 0625T, 0626T) used for reporting Cleerly’s advanced coronary atherosclerosis analysis. Effective January 1, 2024, the AMA published updates to its CPT® code set to include a new Category I CPT® code 75580, described as, “Noninvasive estimate of coronary fractional flow reserve derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified healthcare professional.” The Cleerly ISCHEMIA software outputs an index with its “threshold equivalent to invasive FFR 0.80 vs. ≤0.80 as identified in professional societal practice guidelines.”1

Cleerly® Ischemia™ Software Device Billable With Ama Category I Cpt® Code For Noninvasive Estimates Of Fractional Flow Reserve

Serving as CTO, Steven Borg joins Cleerly from 3motion.

Cleerly refreshes executive team

Cleerly, a Denver-based cardiovascular imaging company, raised $106 million in funding. The round was led by Insight Partners and included Battery Ventures, along with existing investors. The funds will be used to scale commercial growth and clinical evidence generation. Cleerly, led by CEO James K. Min, MD, offers FDA-cleared AI-driven solutions for coronary artery disease phenotyping using advanced CT imaging.

Cleerly Secures $106M for Growth

Viz.ai partners with Cleerly in the name of ai-based CCTA evaluations.

Viz.ai partners with Cleerly in the name of AI-based CCTA evaluations

Join Cleerly Leadership for Live Demonstrations on Advanced Imaging Solutions for Personalized Heart Disease Care. DENVER, Nov. 26, 2024 /PRNewswire/ -- Cleerly, a leader in advanced cardiovascular imaging, is excited to announce its participation in the Radiological Society of North America (RSNA) Conference and Annual Meeting, taking place from December 1 to 5, 2024, at McCormick Place Convention Center in Chicago, Illinois. Onsite, Cleerly leadership will provide live demonstrations of the company's AI-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD). Learn About Cleerly's Technology at Booth 3905

Cleerly Makes Debut At Rsna 2024, Showcasing Ai-Enabled Innovations In Cardiovascular Imaging

Cleerly's recent funding round was led by significant venture capital firms, including GGV Capital and RRE Ventures, among others, reflecting a growing investor interest in health tech solutions.

AI Startup Cleerly Raises $106M for Heart Disease Detection

Although heart disease is the leading cause of death in the United States, a significant portion of people who experience heart attacks are unaware that

Cleerly raises $106M from Insight Partners for AI heart health early detection | TechCrunch

Cleerly, a cardiovascular imaging startup, has announced a significant $106 million Series C extension round led by Insight Partners, with participation from Battery Ventures.

Cleerly Secures $106M in Funding from Insight Partners for AI-Powered Heart Health Early Detection

Machine Vision & HealthTogether with LLMs (large language models) like ChatGPT, machine vision is one of the most important recent developments in AI. The various methods used to achieve it, such as neural networks and deep learning, are now allowing computers to truly see their environment.One application of this idea is letting computers take over humans' tasks like driving or giving robots full autonomy in the real world instead of staying confined to factory floors.It is one one of the large drivers of machine vision adoption, a quickly growing market expected to reach $9.2B by 2029.But another equally important task is judging our health. Many medical diagnoses rely on doctors' visual assessments. This includes direct examination and expert-level analysis of radiography, scanners, and other medical images.In most cases, these visual inspections are somewhat subjective. A doctor will need many years of experience to become truly confident in his assessment. And until now, the complexity of each patient’s body being slightly different made it too complex for automatized measurement.This is finally changing, and many companies are now exploring deploying AI machine vision to create superior analyses of medical images.Direct Visual ExaminationWe recently explored the case of using AI to detect better than human doctor ear infections in our article “AI Poised to Become Invaluable Medical Diagnosis Tool”This can be expanded to many other pathologies; for example, Google's AI imaging can be used to diagnose 26 different skin diseases (80% of cases seen in primary care), detect diabetic retinopathy , or even predict the risk of developing diabetic retinopathy in the future .More surprisingly, AI also appears to be able to detect health issues from visual inspections that humans could not use; for example, detecting anemia (normally requiring a blood test) from a look at the eye’s retina

Ai Machine Vision Looking To Revolutionize Our Health

AI platform for cardiovascular disease diagnosis

Cleerly

AI platform for cardiovascular disease diagnosis

Cleerly

AI platform for cardiovascular disease diagnosis

About

Simplify's Take

What believers are saying

What critics are saying

What makes Cleerly unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Cleerly is Hiring for 0 Jobs on Simplify!